Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) EBITDA Margin (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed EBITDA Margin for 12 consecutive years, with 88.63% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin rose 2588.0% year-over-year to 88.63%, compared with a TTM value of 65.82% through Sep 2025, down 4949.0%, and an annual FY2024 reading of 72.31%, up 6469.0% over the prior year.
  • EBITDA Margin was 88.63% for Q3 2025 at Arcadia Biosciences, down from 34.43% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 709.65% in Q3 2022 and bottomed at 375.3% in Q2 2021.
  • Average EBITDA Margin over 5 years is 29.05%, with a median of 92.05% recorded in 2021.
  • The sharpest move saw EBITDA Margin surged 307274bps in 2021, then crashed -81728bps in 2023.
  • Year by year, EBITDA Margin stood at 215.3% in 2021, then surged by 134bps to 73.02% in 2022, then grew by 9bps to 79.28% in 2023, then tumbled by -337bps to 187.57% in 2024, then surged by 53bps to 88.63% in 2025.
  • Business Quant data shows EBITDA Margin for RKDA at 88.63% in Q3 2025, 34.43% in Q2 2025, and 44.17% in Q1 2025.